Programa de Neurobiología, Universidad Veracruzana, Xalapa, Mexico.
Clin Interv Aging. 2011;6:53-9. doi: 10.2147/CIA.S14008. Epub 2011 Feb 22.
Alzheimer's disease (AD) is the most common neurodegenerative disorder, originating sporadically in the population aged over 65 years, and advanced age is the principal risk factor leading to AD development. In spite of the large amount of research going on around the globe and all the information now available about AD, there is still no origin or triggering process known so far. Drugs approved for the treatment of AD include tacrine, donepezil, rivastigmine, galantamine, and memantine. These may delay or slow down the degenerative process for a while, but they can neither stop nor reverse its progression. Because that this might be due to a lack of effect of these drugs on degenerating neurons, even when they are able to potentiate the brain in nondegenerative conditions, we propose here an alternative therapy consisting of initial repair of neuronal membranes followed by conventional drug therapies. The rehabilitation of neurons in a degeneration process would enable the drugs to act more effectively on them and improve the effects of treatment in AD patients.
阿尔茨海默病（AD）是最常见的神经退行性疾病，起源于 65 岁以上人群中的散发性病例，而年龄增长是导致 AD 发展的主要危险因素。尽管全球范围内进行了大量研究，并且现在有关于 AD 的大量信息，但迄今为止，仍不清楚其起源或触发过程。批准用于治疗 AD 的药物包括他克林、多奈哌齐、利斯的明、加兰他敏和美金刚。这些药物可能会在一段时间内延缓或减缓退行性过程，但既不能阻止也不能逆转其进展。因为这可能是由于这些药物对退行性神经元的作用缺乏效果，即使它们能够在非退行性条件下增强大脑，我们在这里提出一种替代疗法，包括初始修复神经元膜，然后再进行常规药物治疗。在退行性过程中修复神经元，将使药物更有效地作用于神经元，并改善 AD 患者的治疗效果。
